**Periodontitis Prevalence and Severity in Inflammatory Bowel Disease: A Case-Control Study**

# Periodontitis prevalence and severity in inflammatory bowel disease: a case-control study

Giacomo Baima DDS, MS[*†]; Mamdouh Muwalla DDS[*]; Giulia Testa MD[‡]; Francesca Mazza[*]; Ahmad Bebars DDS, MS[*]; Stefano Perotto DDS, MS[*]; Marta Vernero MD[‡]; Alessandro Massano MD[‡]; Federica Romano DDS, PhD[*]; Davide Giuseppe Ribaldone MD[‡]; Mario Aimetti MD, DDS[*]

**Corresponding author:**

Giacomo Baima DDS, MS

Department of Surgical Sciences, C.I.R. Dental School, University of Turin, Italy

via Nizza 230, Turin, Italy

E-mail address: giacomo.baima@unito.it

**Word count:** 3.052

**Tables and figures:** 5

**References:** 42

**Running title:**

Prevalence of periodontitis in patients with IBD

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/JPER.11025.

[*] *Department of Surgical Sciences, C.I.R. Dental School, University of Turin, Turin, Italy.*

[†] *Politecnico di Torino, Turin, Italy.*

[‡] *Department of Medical Sciences, University of Turin, Turin, Italy.*

**One-sentence summary:**

In the present case-control study, a significantly higher frequency of periodontitis was observed in patients with inflammatory bowel disease compared to healthy controls, with some peculiar clinical characteristics of Crohn's disease and ulcerative colitis identified as risk indicators.

**Author contributions:**

All authors made substantial contributions and have given final approval of the version of the manuscript to be published. GB, FR, DGR, MA contributed to the conception and design of the study. MM, GT, FM, SP contributed to the data acquisition of the study. GB, FR, SP have been involved with data analysis. All authors have been involved with data interpretation. GB, FR, GT, DGR, and MA drafted the manuscript. All authors provided critical revision of the manuscript and they are responsible for the integrity of the data used in this manuscript.

**Data availability:**

The data that support the findings of this study are available from the corresponding author upon request.

## Abstract

**Background:** Recent evidence is supporting the notion of a microbiological and immunological continuum on the gum-gut axis in health and disease. Therefore, the purpose of this study was to assess the prevalence and risk indicators of periodontitis in patients with Crohn's disease (CD) or ulcerative colitis (UC) compared to age- and gender-matched controls without inflammatory bowel disease (IBD).

**Material and Methods:** One hundred eighty IBD (117 CD, 60 UC, 3 IBD-unclassified) and 180 healthy controls were compared for their periodontitis diagnosis (CDC/AAP case definition) and full-mouth periodontal parameters. In addition, explorative logistic regression models were performed.

**Results:** Significantly more patients with IBD had moderate/severe periodontitis (85.6% vs 65.6%, $p<0.001$) and severe periodontitis (36.7% vs 25.6%, $p<0.001$) than controls. Differences were higher in the 35-50 and 51-65 age groups, without significant changes between CD and UC. IBD subjects presented chances ~3.5 higher of having moderate/severe periodontitis ($p<0.001$). Significant variables associated with periodontitis in the whole sample were older age, presence of IBD, and higher full-mouth plaque scores; whereas in the IBD group they were gender (male), IBD-associated surgery, IBD duration and localization (pancolitis). Positive risk indicators for IBD were periodontitis severity and higher bleeding scores, while smoking was negatively associated with UC.

**Conclusions:** Relevant associations between IBD and periodontitis were found, being modified by CD and UC clinical characteristics. Preventive and therapeutic strategies involving the gum-gut axis should be enforced in IBD patients.


**Keywords**: Case-control Study, Inflammation, Inflammatory Bowel Disease, Periodontal medicine, Periodontitis.

## Introduction

Inflammatory bowel disease (IBD) is a group of chronic and relapsing disorders of the gastrointestinal tract, Crohn's disease (CD) and Ulcerative Colitis (UC) being the main forms. IBD has emerged as a global public health challenge, with its incidence progressively increasing by 31% from 1990 to 2017, especially in developed countries.[1,2] The pathogenesis of IBD is not yet fully elucidated, involving genetic predisposition, environmental factors, gut microbial dysbiosis and dysregulated immune response.[3] The most common symptoms are abdominal cramps, vomiting, bloody diarrhea, urge to evacuate, tenesmus, fatigue, and weight loss, characterized by phases of quiescence and phases of flare-up of the disease.[4] CD can present with deep lesions of the gastrointestinal wall from the mouth to the anus, whereas UC affects the mucosa of the colon and rectum in a continuous way, with presence of erythema, erosions, and ulcers.[5] Besides intestinal inflammatory activity and complications, which may require surgical treatment, extra-intestinal manifestations in IBD can occur in joints, skin, eyes, and mouth.[6,7] The goal of IBD therapy is to induce and maintain remission, with the current paradigm implicating a step-up modality moving to more invasive therapies (i.e., surgical resection of the inflamed gastrointestinal tract) only when milder therapies (i.e., corticosteroids, aminosalicylates, or immunomodulators) fail to reach the outcomes.[8]

Periodontitis represents the sixth most common human disease, affecting from 10 to 34% of the population in its more severe forms.[9,10] On the top of being the main cause leading to tooth loss in the adults, chronic gum infection/inflammation underpinning periodontitis may lead to relapsing bacteremia, elevation of the systemic low-grade inflammatory burden, autoimmune dysregulations, and bacterial translocation to lower respiratory tract and digestive system.[11] In the light of these mechanisms, periodontitis has been robustly associated with a wide range of systemic diseases, including cardiovascular diseases, diabetes, respiratory diseases, and gastrointestinal diseases.[12–14]

Following recent evidence that oral and gut environments are closely related under the microbiological and immunological perspective, a plausible bidirectional association between periodontitis and IBD is receiving growing scientific interest.[15,16] Recent meta-epidemiologic data

indicated that IBD was associated with higher Decayed, Missing, Filled Teeth (DMFT) indexes[17] and a significantly increased risk of periodontitis compared to non-IBD patients.[18,19] However, most of the available literature presented arbitrary case definitions for periodontitis, inaccurate assessment of the outcomes, uneven samples of IBD and non-IBD patients, and the risk of residual confounders in the analyses.[20–23]

Therefore, the primary aim of this study was to investigate the prevalence of periodontitis in a sample of patients with CD and UC compared to an age and gender-matched control group of patients without IBD. The secondary aim was to explore the association between IBD activity and other disease characteristics including systemic markers of inflammation with the severity of periodontitis.

## Materials and Methods

### *Patient selection*

This case-control, cross-sectional study was conducted in accordance with the Helsinki Declaration and approved by the Institutional Ethical Committee of the "AOU Città della Salute e della Scienza" of Turin (cod.: 00066/2021), and it complies with the STROBE guidelines.[24] All participants signed an informed consent to undergo physical and periodontal examination.

Individuals treated as outpatients for IBD at the Department of Medical Sciences, University of Turin, were consecutively recruited from September 2020 to December 2021. The diagnosis of either CD or UC was confirmed by previously established clinical, radiological and endoscopic criteria.[25] Moreover, histological findings also had to be confirmative or compatible with this diagnosis. The same number of non-IBD subjects consecutively selected from the C.I.R. Dental School, University of Turin, were compared with the study patients. Patients with IBD (cases) and the control group were recruited from the same population (Turin, North Italy). The control group and patients with IBD were matched referring to age, sex and ethnicity.

The following inclusion criteria were considered: (i) at least 18 years of age; (ii) having at least 6 teeth (independently from wearing dental prostheses); (iii) availability of measurements of routine IBD-related laboratory tests made (C-reactive protein, calprotectin). Exclusion criteria were: (i) diabetes mellitus; (ii) intake of drugs known to affect gingival tissues; (iii) periodontal therapy in the past 3 months; (iv) pregnancy or lactation; and (v) diagnosis of following pathologies: cancer, human immunodeficiency virus/AIDS, liver/kidney failure.

*Clinical examination*

Participants were required to complete a questionnaire to obtain information on socio-demographic characteristics [gender (man/woman), age (years), education (low: primary and secondary school level; intermediate: high school diploma; high: university degree)], smoking behavior (light smoker < 10 cigarettes/day, heavy smoker ≥ 10 cigarettes/day), and oral hygiene behavior [frequency of dental examinations and professional oral hygiene sessions (sporadically, once/year, at least twice/year), toothbrushing frequency (≤ once/day, twice/day, more than twice/day), use of interdental devices (yes/no)].

Baseline characteristics also included years from IBD diagnosis, localization [for UC: E1= proctitis; E2= left-sided UC; E3= pancolitis; for CD: L1= ileal; L2= colonic; L3= ileocolonic (Montreal Classification)[26]] and extraintestinal manifestations (yes/no), previous surgery (ostomy or bowel resection; yes/no), hypertension (yes/no), C-reactive protein (CRP; mg/L), and fecal calprotectin (mg/kg). Disease activity of CD was assessed using Harvey-Bradshaw index [(HBI) < 5: remission; 5-7: mild disease; 8-16: moderate disease; > 16: severe disease],[27] whereas disease activity of UC was assessed using the partial Mayo Score [(PMI) < 2: remission; 2-4: mild activity; 5-7: moderate activity; > 7: severe activity].[28]

Patients received standard medical treatment including corticosteroids (prednisone or oral budesonide), immunosuppressants (e.g., azathioprine), amino-salicylate (e.g. 5-ASA), target therapies

(e.g., anti-TNF, vedolizumab, ustekinumab) and antibiotics as mono- or combination therapy. None of the patients of the control group received any of the above-mentioned medical treatments.

*Periodontal examination*

The intra-oral examinations were conducted using a dental chair and included the presence of plaque and periodontal measurements [bleeding on probing (BoP), probing pocket depth (PPD), recession (Rec), clinical attachment level (CAL)].

Full-mouth PPD, BoP, Rec and CAL were assessed at six sites per tooth, excluding third molars. The total percentages of sites exhibiting bacterial plaque or BoP were expressed as full mouth plaque score (FMPS) and full mouth-bleeding score (FMBS), respectively. The number of missing teeth was also recorded. All measurements were performed by means of a periodontal probe with 1-mm markings[§] and the readings were recorded to the nearest 1 mm. The PPD was measured from the gingival margin to the base of the probable sulcus/pocket. The presence or absence of BoP was recorded after 30 seconds. The CAL represented the distance between the cementoenamel junction (CEJ) and the base of the probable sulcus/pocket. In case a restoration extended apically to the CEJ or an abrasion was present at the tooth cervix, the position of the CEJ was estimated by extrapolating the position of the CEJ from the adjacent teeth. Measurements were taken by two calibrated examiners throughout the study for patients with IBD and controls, achieving substantial inter – examiner reproducibility (k ranging from 0.72 to 0.86, $p<0.001$) for all the variables analyzed.

The presence of periodontitis was defined according to the criteria proposed by Centers for Disease Control and Prevention/American Academy of Periodontology (CDC/AAP) for epidemiologic surveys.[29,30] Therefore, moderate periodontitis was defined as at least 2 interproximal sites with attachment loss ≥ 4 mm (not on the same tooth) or at least 2 interproximal sites with PPD ≥ 5 mm, also

§ PCP-UNC 15, Hu-Friedy, Chicago, IL, USA

not on the same tooth. The presence of at least 2 interproximal sites with attachment loss ≥ 6 mm (not on the same tooth) and at least 1 interproximal site with PPD ≥ 5 mm indicated severe periodontitis. If neither moderate nor severe periodontitis applied, no/mild periodontitis was recorded. Moreover, a confirmatory analysis was carried out by utilizing the current clinical classification of periodontal diseases,[31] as reported in the Appendix.[32]

*Statistical analysis*

Sample size calculation was based on an expected prevalence of periodontitis of 85% among IBD individuals compared to 70% among non-IBD controls[21] using the Fleiss method through the OpenEpi software (version 3.01, Boston, USA). Based on an alpha error of 0.05, a power of 0.90, and a case–control ratio of 1:1, a total of 360 individuals (180 cases and 180 controls) were enrolled.

Descriptive analysis such as frequencies, percentages and mean with standard deviation (SD) or median with interquartile (IQR) was used where appropriate. The Shapiro–Wilk test and Q-Q normality plots were applied to verify the normal distribution of quantitative variables. The homogeneity of variances was assessed by the Levene test. The $\chi 2$ test was used to evaluate any potential association between categorical variables and the independent t-test (for variables with Gaussian distribution) and the Mann-Whitney U-test (for variables without a Gaussian distribution) to assess differences of quantitative variables between case and control groups and between CD and UD subjects.

Explorative multiple logistic regression models were developed using backward method to identify risk indicators of IBD (yes vs. no) and total periodontitis (yes vs. no) among all the enrolled subjects and for different IBD diagnosis. Selection of potential statistically (p value < 0.25 in the univariate analyses) and clinically relevant variables was conducted.[33] Data were presented as odds ratio (OR) and 95% confidence intervals (CI). The significance level was set at 5% ($p < 0.05$) and statistical analysis was carried out using the Statistical Package for the Social Sciences (SPSS), version 25.0 software (Chicago, IL, USA).

**Results**

A total of 180 IBD patients (117 CD, 60 UC, 3 IBD-unclassified -> IBD-U) and 180 age- and gender-matched controls were enrolled. Data from the 3 IBD-U patients were pooled within the total IBD sample, although they were not included in the subgroup analyses.

Table 1 provides descriptive statistics of the study participants, both overall and categorized for IBD types. All participants were Caucasian, with a mean age of 48.4 (± 15.3) years in the case group and 47.8 (± 14.3) years in the control group. No statistically significant differences were found for any socio-demographic variable between healthy and diseased individuals, nor between the different IBD manifestations. All participants had a balanced diet, with none to moderate alcohol consumption. Significant differences were found among groups with respect to oral hygiene habits, with IBD patients reporting higher flossing habits and frequencies of professional hygiene recalls than controls ($p<0.001$). When comparing CD and UC patients, the latter had received less surgical interventions and smoked less ($p<0.05$).

Periodontal parameters are reported in Table 2. The number of teeth did not differ between patients with IBD versus healthy controls. A significantly higher prevalence of periodontitis was found for IBD patients compared to controls (85.6% vs 65.6%; $p<0.001$). Both moderate (48.9% vs 40.0%) and severe periodontitis (36.7% vs 25.6%) were more frequent in IBD patients ($p<0.001$) than controls, without any significant differences between CD and UC. As expected, PPD and CAL values, as well as number of deep pockets (PPD $\geq$ 5 mm) were significantly higher than IBD-free subjects. Confirmatory analysis using the 2018 classification showed how stage III-IV periodontitis were significantly more represented in IBD than in controls (see Table S1 in online Journal of Periodontology).

Periodontal data stratified by age are reported in Table 3. Individuals aged between 36 and 50 years presented a significantly higher prevalence of moderate and severe periodontitis ($p<0.005$), higher CAL and PPD values, as well as a higher number of deep pockets compared to controls ($p<0.05$).

Moreover, individuals aged between 51 and 65 suffered from severe periodontitis more frequently than age-matched controls, also showing higher CAL values (both $p<0.05$).

Table 4 shows four final logistic regression models with significant positive predictors and adjusted OR estimates for periodontitis (dependent variable) stratified by IBD forms. (a) Model 1 (all sample)—age, FMPS, and presence of IBD; (b) Model 2 (only IBD)—age, male sex, IBD-associated surgery, IBD localization (ileum + colon); Model 3 (only CD)—age, male sex, FMBS, CD localization (ileum + colon); Model 4 (only UC)—age, UC localization (pancolitis), UC duration (negative predictor).

Table 5 shows three final logistic regression models with significant variables and adjusted OR estimates for IBD, CD, and UC (dependent variables). (a) Model 1 (IBD)—moderate and severe periodontitis as well as higher FMBS were significant positive predictors of IBD, while light smoking decreased the odds of having the condition; (b) Model 2 (CD) and Model 3 (UC) confirmed the previous associations, except for smoking that was negatively associated only to UC.

## Discussion

The current study revealed that the prevalence of periodontitis and severe periodontitis is significantly higher in IBD patients compared to age- and gender- matched healthy controls. Even if subgroup analyses often lack power, in the study sample the association was the strongest in the age group from 35 to 50 years and it remained significant from 51 to 65 years. Individuals with IBD consistently presented with significantly worse periodontal clinical parameters, while no differences were encountered between CD and UC.

This case-control study confirms the findings from previous meta-analyses which found a significantly higher prevalence of periodontitis in patients with both CD and UC.[18,34] The present data are highly concordant with the results of Brito et al.,[21] who found higher prevalence of periodontitis of 82% in CD, 90% in UC, and 68% in controls. Conversely, some other studies failed to produce evidence

for a correlation between IBD and periodontal disease. Grössner-Schreiber et al.[20] observed no distinct periodontal diagnosis between cases and controls, despite patients with IBD having slightly more sites with CAL ≥ 4 mm. Moreover, a recent study with a similar design found that the frequency of periodontal diseases did not significantly differ among IBD and non-IBD groups, as determined by the Dutch Periodontal Screening Index.[23] These conflicting results may arise from different periodontitis case definitions and thresholds employed. Moreover, using simplified periodontal screening examinations or partial mouth assessments pose the risk of underestimating the disease, especially in younger populations.[35] Indeed, the present study used a full-mouth examination protocol and it was the first to apply the CDC/AAP classification system.[36] In an attempt to minimize misclassification, solely CDC/AAP algorithms for moderate/severe periodontitis were implemented and only patients with a minimum number of 6 teeth were enrolled.[37]

IBD are complex diseases, with their development and progression being influenced by (epi)genetic determinants and environmental factors leading to a disturbed host-microbiome interplay.[38] Since several of these IBD-relevant influences are also risk factors for periodontitis,[18] multiple logistic models were built to explore the relative contribution of potential risk indicators and to generate hypothesis for future studies. Within the present sample, having IBD was an independent risk indicator for periodontitis, together with increasing age and FMPS. Individuals with IBD presented a chance ~3 and ~4.5 higher of having moderate and severe periodontitis, respectively. Besides male sex, the extension of the gut mucosal inflammation was a significant predictor of periodontitis in both CD and UC. It may be hypothesized that a more severe inflammatory burden of IBD may correlate with periodontal damage. Contrary to most studies, we determined clinical disease activity by established scores (HBI and PMI) and biochemical markers. Nevertheless, these scores were not associated with periodontitis. It has to be remarked that the present sample was composed of outpatients with IBD with current remission or in low activity phase. Indeed, most of them had a long history of medical treatment with immunosuppressants and a consistent group already underwent intestinal resection. Since longer disease duration and IBD-associated surgery were negatively associated with periodontitis, it may be speculated that having IBD under control may play a protective role.

When the inverse inferential pathway was explored, the probability of having IBD appeared associated with the severity of periodontitis and the increasing of the bleeding score. Interestingly, either being a light or a heavy smoker was negatively associated with UC, but it did not have an effect on CD. Paradoxically, cigarette smoking appears to decrease the risk for UC in epidemiologic studies, although the mechanisms involved have not yet fully been clarified.[39]

Both periodontitis and IBD develop from a disproportionate mucosal inflammatory response to microbial dysbiosis in susceptible patients.[11,40] The fact that IBD and periodontitis were more significantly associated in the middle age categories (36-50 and 51-65 years) can point to an increased inflammatory reactivity in patients with immune-mediated diseases, which is also indicated by a higher FMBS compared to similar levels of biofilm accumulation and higher oral hygiene care (use of interdental devices and regular attendance to professional prophylaxis) in patients with IBD. It can be thus hypothesized that both UC and CD patients possess a hyper-inflammatory phenotype at the oral mucosal level, which may be consistent with the pathogenesis of the gut disease.[15] Recent available evidence suggests different plausible pathways of interaction between periodontitis and IBD along the gum-gut axis, including the hematogenous, the enteral, and the immunological routes.[16] Indeed, both periodontal pathobionts and orally-primed Th17 cells can translocate to the intestinal tract, where they can activate the inflammasome in colonic macrophages, exacerbating mucosal inflammation.[41]

Compared to the previous investigations, the present study relies on the standards for reporting periodontitis prevalence and severity, a larger sample size, and the presence of a well-balanced control group. Furthermore, the regression models firstly identified explorative risk indicators for the IBD-periodontitis interrelationship. Limitations worth mentioning are related to the sample of patients that may be considered not representative of the whole population, since recruited in two university-based IBD and dental centers located in Northern Italy. This may limit the generalizability of the present findings. Furthermore, due to the multifactorial etiology of both diseases, the risk of residual confounders in the analyses could not be ruled out, such as changed dietary habits[42] and chronic drug intake in IBD group (corticosteroids and/or immunomodulators) which may influence periodontal status. In the present study, the current case definition for epidemiological surveys, as well as the most

updated criteria for periodontitis clinical classification were employed. These implemented algorithms are prevalently based on CAL and PPD and do not differentiate between bleeding or not bleeding sites, making it difficult to infer on the active burden of periodontitis on the systemic disease. Well-designed longitudinal studies taking into account the presence of active periodontal inflammation are warranted to better clarify this aspect.

## Conclusions

Overall, the present study demonstrated a relevant association between IBD and periodontitis, particularly in the 36-50 age category. Despite CD or UC patients having the same prevalence of periodontitis, some disease-specific variables were found to modify the association, such as the extension of the gut mucosal inflammation and the history of treatment. Both clinicians and public health administrators should consider that IBD patients may benefit from tailored interdisciplinary preventive and therapeutic programs involving the gum-gut axis.

## Conflict of interest and source of funding:

The authors do not have any financial interests, either directly or indirectly, in the information listed in the paper.

## Bibliography

1. Kaplan GG. The global burden of IBD: from 2015 to 2025. *Nat Rev Gastroenterol Hepatol.* 2015;12:720–727.

2. Tursi A, Elisei W, Picchio M. Incidence and prevalence of inflammatory bowel diseases in gastroenterology primary care setting. *Eur J Intern Med.* 2013;24:852–856.

3. de Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. *Nat Rev Gastroenterol Hepatol.* 2017;14:739–749.

4. Ribaldone DG, Pellicano R, Actis GC. The gut and the inflammatory bowel diseases inside-out: extra-intestinal manifestations. *Minerva Gastroenterol Dietol.* 2019;65:309–318.

5. Actis GC, Pellicano R, Fagoonee S, Ribaldone DG. History of inflammatory bowel diseases. *J Clin Med.* 2019;8:E1970.

6. Ribaldone DG, Brigo S, Mangia M, Saracco GM, Astegiano M, Pellicano R. Oral manifestations of inflammatory bowel disease and the role of non-invasive surrogate markers of disease activity. *Medicines (Basel).* 2020;7:E33.

7. Rosso C, Aaron AA, Armandi A, et al. Inflammatory bowel disease nurse—practical messages. *Nurs Rep.* 2021;11:229–241.

8. Neurath MF. Current and emerging therapeutic targets for IBD. *Nat Rev Gastroenterol Hepatol.* 2017;14:269–278.

9. GBD 2017 Oral Disorders Collaborators, Bernabe E, Marcenes W, Hernandez CR, et al. Global, regional, and national levels and trends in burden of oral conditions from 1990 to 2017: a systematic analysis for the global burden of disease 2017 study. *J Dent Res.* 2020;99:362–373.

10. Aimetti M, Perotto S, Castiglione A, Mariani GM, Ferrarotti F, Romano F. Prevalence of periodontitis in an adult population from an urban area in North Italy: findings from a cross-sectional population-based epidemiological survey. *J Clin Periodontol.* 2015;42:622–631.

11. Hajishengallis G, Chavakis T. Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities. *Nat Rev Immunol.* 2021;21:426–440.

12. Genco RJ, Sanz M. Clinical and public health implications of periodontal and systemic diseases: An overview. *Periodontol 2000.* 2020;83:7–13.

13. Baima G, Ribaldone DG, Muwalla M, et al. Can periodontitis affect the health and disease of the digestive system? A comprehensive review of epidemiological evidence and biological mechanisms. *Curr Oral Health Rep.* 2021;8:96–106.

14. Baima G, Marruganti C, Sanz M, Aimetti M, Romandini M. Periodontitis and COVID-19: Biological Mechanisms and Meta-analyses of Epidemiological Evidence. *J Dent Res*. 2022; doi: 10.1177/00220345221104725.

15. Kitamoto S, Nagao-Kitamoto H, Hein R, Schmidt TM, Kamada N. The bacterial connection between the oral cavity and the gut diseases. *J Dent Res*. 2020;99:1021–1029.

16. Baima G, Massano A, Squillace E, et al. Shared microbiological and immunological patterns in periodontitis and IBD: A scoping review. *Oral Dis.* 2022;28:1029–1041.

17. Marruganti C, Discepoli N, Gaeta C, Franciosi G, Ferrari M, Grandini S. Dental Caries Occurrence in Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. *Caries Res.* 2021;55:485–495.

18. Papageorgiou SN, Hagner M, Nogueira AVB, Franke A, Jäger A, Deschner J. Inflammatory bowel disease and oral health: systematic review and a meta-analysis. *J Clin Periodontol.* 2017;44:382–393.

19. Zhang Y, Qiao D, Chen R, Zhu F, Gong J, Yan F. The association between periodontitis and inflammatory bowel disease: a systematic review and meta-analysis. *Biomed Res Int.* 2021;2021:6692420.

20. Grossner-Schreiber B, Fetter T, Hedderich J, Kocher T, Schreiber S, Jepsen S. Prevalence of dental caries and periodontal disease in patients with inflammatory bowel disease: a case-control study. *J Clin Periodontol.* 2006;33:478–484.

21. Brito F, Barros FC de, Zaltman C, et al. Prevalence of periodontitis and DMFT index in patients with Crohn's disease and ulcerative colitis. *J Clin Periodontol.* 2008;35:555–560.

22. Vavricka SR, Manser CN, Hediger S, et al. Periodontitis and gingivitis in inflammatory bowel disease: a case–control study. *Inflamm Bowel Dis*. 2013;19:2768–2777.

23. Tan CXW, Brand HS, Kalender B, De Boer NKH, Forouzanfar T, de Visscher JGAM. Dental and periodontal disease in patients with inflammatory bowel disease. *Clin Oral Invest.* 2021;25:5273–5280.

24. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. *Int J Surg.* 2014;12:1500–1524.

25. Kucharzik T, Ellul P, Greuter T, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. *J Crohns Colitis.* 2021;15:879–913.

26. Satsangi J, Silverberg MS, Vermeire S, Colombel J. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. *Gut*. 2006;55:749–753.

27. Peyrin-Biroulet L, Panés J, Sandborn WJ, et al. Defining disease severity in inflammatory bowel diseases: current and future directions. *Clin Gastroenterol Hepatol*. 2016;14:348-354.

28. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. *Inflamm Bowel Dis*. 2008;14:1660–1666.

29. Page RC, Eke PI. Case definitions for use in population-based surveillance of periodontitis. *J Periodontol.* 2007;78 Suppl 7:1387–1399.

30. Eke PI, Page RC, Wei L, Thornton-Evans G, Genco RJ. Update of the case definitions for population-based surveillance of periodontitis. *J Periodontol.* 2012;83:1449–1454.

31. Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, et al. Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. *J Periodontol.* 2018;89 Suppl 1:S173–182.

32. Jiao J, Jing W, Si Y, et al. The prevalence and severity of periodontal disease in Mainland China: Data from the Fourth National Oral Health Survey (2015–2016). *J Clin Periodontol*. 2021;48:168–179.

33. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. *Source Code Biol Med*. 2008;3:17.

34. She YY, Kong XB, Ge YP, et al. Periodontitis and inflammatory bowel disease: a meta-analysis. *BMC Oral Health*. 2020;20:67.

35. Romano F, Perotto S, Castiglione A, Aimetti M. Prevalence of periodontitis: misclassification, under-recognition or over-diagnosis using partial and full-mouth periodontal examination protocols. *Acta Odontol Scand*. 2019;77:189–196.

36. Holtfreter B, Albandar JM, Dietrich T, et al. Standards for reporting chronic periodontitis prevalence and severity in epidemiologic studies: Proposed standards from the Joint EU/USA Periodontal Epidemiology Working Group. *J Clin Periodontol.* 2015;42:407–412.

37. Romano F, Perotto S, Mohamed SEO, et al. Bidirectional association between metabolic control in type-2 diabetes mellitus and periodontitis inflammatory burden: a cross-sectional study in an Italian population. *J Clin Med.* 2021;10:1787.

38. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature*. 2012;491:119–124.

39. Bastida G, Beltrán B. Ulcerative colitis in smokers, non-smokers and ex-smokers. *World J Gastroenterol*. 2011;17:2740–2747.

40. Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. *Clin J Gastroenterol.* 2018;11:1–10.

41. Kitamoto S, Nagao-Kitamoto H, Jiao Y, et al. The intermucosal connection between the mouth and gut in commensal pathobiont-driven colitis. *Cell*. 2020;182:447-462.

42. Marruganti C, Traversi J, Gaeta C, et al. Adherence to Mediterranean diet, physical activity level, and severity of periodontitis: Results from a university-based cross-sectional study. *J Periodontol.* 2022; doi: 10.1002/JPER.21-0643.

## Appendix

### Materials and methods

Periodontal disease was diagnosed according to the classification scheme proposed at the 2018 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions as follows: periodontally healthy: <10% bleeding on probing (BOP)-positive teeth and probing pocket depth (PPD) ≤3 mm; gingivitis: ≥10% BOP-positive teeth and PPD ≤3 mm; and Periodontitis was staged using the algorithm developed by Graetz et al.[1] For each tooth, clinical attachment level (CAL) of the most severe sites was recorded, and a CAL of 1–2 mm was defined as stage I, 3–4 mm as stage II, and ≥5 mm as stage III. Next, the number of missing teeth was considered (stages I and II, no tooth missing; stage III, ≤4 teeth missing; and stage IV, ≥5 teeth missing). We also evaluated the complexity of management. Stage II patients were reclassified as stage III if the maximum PPD was ≥6 mm. Stage III patients were reclassified as stage IV if there were less than 20 remaining teeth or 10 opposing pairs.

### Appendix references

1. Graetz C, Mann L, Krois J, Sälzer S, Kahl M, Springer C, et al. Comparison of periodontitis patients' classification in the 2018 versus 1999 classification. *J Clin Periodontol*. 2019;46:908–917.

**Table 1.** Patient and Disease Characteristics

| **Variables** | **IBD** (n = 180) | **CD** (n = 117) | **UC** (n = 60) | **Controls** (n = 180) |
|---|---|---|---|---|
| Male (n, %) | 102 (56.7) | 61 (52.1) | 39 (65.0) | 103 (57.2) |
| Age at examination (mean ± SD) | 48.4 ± 15.3 | 47.9 ± 13.6 | 49.3 ± 17.8 | 47.8 ± 14.3 |
| Education level | | | | |
| Low (n, %) | 51 (34.7) | 35 (36.8) | 13 (32.0) | 71 (39.4) |
| Intermediate (n, %) | 73 (49.7) | 44 (46.3) | 27 (54.0) | 74 (41.1) |
| High (n, %) | 23 (15.6) | 16 (16.8) | 7 (14.0) | 35 (19.4) |
| IBD duration (mean ± SD) | 15.8 ± 10.9 | 16.5 ± 10.5 | 14.9 ± 11.8 | NA |
| Disease activity | | | | |
| Partial Mayo (mean ± SD) | NA | NA | 1.31 ± 1.69 | NA |
| HBI (mean ± SD) | NA | 3.27 ± 2.87 | NA | NA |
| IBD-associated surgery (n, %) | 80 (44.4) | 65 (55.6) | 15 (25.0)[a] | NA |
| CRP mg/L (mean ± SD) | 6.2 ± 10.8 | 5.1 ± 8.9 | 8.2 ± 13.6 | NA |
| Fecal calprotectin µg/g (mean ± SD) | 388.7 ± 641.3 | 369.9 ± 652.7 | 408.8 ± 624.5 | NA |
| Localization (n, %) | | | | |
| E1 ( | NA | NA | 6 (10.0) | NA |
| E2 | NA | NA | 15 (25.0) | NA |
| E3 | NA | NA | 39 (65.0) | NA |
| L1 | NA | 45 (38.5) | NA | NA |
| L2 | NA | 19 (16.2) | NA | NA |
| L3 | NA | 53 (45.3) | NA | NA |
| Extraintestinal manifestation (n, %) | 18 (10.2) | 14 (12.0) | 4 (6.9) | NA |
| Drugs (n, %) | | | | |

| | | | | |
|---|---|---|---|---|
| Systemic steroids | 12 (6.7) | 7 (6.0) | 4 (6.7) | NA |
| Budesonide | 31 (17.2) | 14 (12.0) | 17 (28.3) | NA |
| Targeted therapies | 48 (26.7) | 36 (30.8) | 11 (18.3) | NA |
| Aminosalicylates | 116 (64.4) | 73 (62.4) | 41 (68.3) | NA |
| Oral health practices | | | | |
| Flossing (n, %) | 119 (66.1)[b] | 76 (65.0) | 41 (68.3) | 62 (34.4) |
| Brushing frequency (n, %) | | | | |
| ≤ once/day | 23 (13.1) | 16 (14.0) | 5 (8.5) | 29 (16.1) |
| twice/day | 98 (55.7) | 63 (55.3) | 34 (57.6) | 80 (44.4) |
| ≥ three times/day | 55 (31.3) | 35 (30.7) | 20 (33.9) | 71 (39.4) |
| Regular scaling frequency (n, %) | | | | |
| Sporadically | 94 (54.0) [b] | 62 (54.4) | 31 (54.4) | 114 (63.3) |
| once/year | 28 (16.1) | 18 (15.8) | 10 (17.5) | 54 (30.0) |
| ≥ twice/year | 52 (29.9) | 34 (29.8) | 16 (28.1) | 12 (6.7) |
| Smoking (n, %) | | | | |
| No | 131 (72.8) | 78 (66.7) | 52 (86.7)[a] | 116 (64.4) |
| Light | 20 (11.1) | 17 (14.5) | 2 (3.3) | 31 (17.2) |
| Heavy | 29 (16.1) | 22 (18.8) | 6 (10.0) | 33 (18.3) |

**Abbreviations:** IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; HBI, Harvey-Bradshaw Index; CRP, C-reactive protein; E1, proctitis; E2, left-sided UC; E3, pancolitis; L1, ileal; L2, colonic; L3, ileocolonic; NA, not assessable.

Statistical significance: [a], CD vs UC $p<0.05$; [b], IBD vs controls $p<0.05$

**Table 2.** Group comparison of patients with IBD and controls with regards to periodontal parameters

| **Variables** | **IBD** (n = 180) | **CD** (n = 117) | **UC** (n = 60) | **Controls** (n = 180) |
|---|---|---|---|---|
| Diagnosis | | | | |
| No/mild periodontitis (%) | 26 (14.4)[a] | 17 (14.5) | 9 (15.0) | 62 (34.4) |
| Moderate periodontitis (%) | 88 (48.9)[a] | 59 (50.4) | 28 (46.7) | 72 (40.0) |
| Severe periodontitis (%) | 66 (36.7)[a] | 41 (35.0) | 23 (38.3) | 46 (25.6) |
| Moderate/severe periodontitis (%) | 154 (85.6)[a] | 100 (85.4) | 51 (85.0) | 118 (65.6) |
| Periodontal parameters | | | | |
| Number of teeth (median, IQR) | 26 (4) | 26 (5) | 26 (4) | 26 (5) |
| FMPS (median, IQR) | 60.7 (42.3) | 57.4 (43.2) | 64.3 (42.8) | 47.9 (43.1) |
| FMBS (median, IQR) | 33.6 (40.5) | 32.7 (40.3) | 31.1 (34.9) | 27.5 (25.8) |
| PPD (median, IQR) | 3.0 (0.8)[a] | 3.0 (0.8) | 3.0 (0.7) | 2.6 (0.6) |
| CAL (median, IQR) | 3.1 (0.9)[a] | 3.0 (0.9) | 3.1 (0.7) | 2.7 (0.7) |
| Number of PPD ≥ 5 mm (median, IQR) | 8.0 (14.5)[a] | 7.0 (16.5) | 8.5 (13.8) | 4.0 (16.0) |

**Abbreviations:** IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; FMPS, full-mouth plaque score; FMBS, full-mouth bleeding score; PPD, probing pocket depth; CAL, clinical attachment level; IQR, interquartile range.

[a], IBD vs controls $p<0.001$; [b], CD vs UC $p<0.05$

**Table 3.** Group comparison of patients with IBD and controls with regards to periodontal parameters stratified by age

| **Variables** | **Age 18-35** | | **Age 36-50** | | **Age 51-65** | | **Age > 65** | |
|---|---|---|---|---|---|---|---|---|
| | IBD (n = 38) | Controls (n = 38) | IBD (n = 59) | Controls (n = 62) | IBD (n = 56) | Controls (n = 54) | IBD (n = 27) | Controls (n = 26) |
| Diagnosis | | | | | | | | |
| No/mild periodontitis (%) | 14 (36.8) | 19 (50.0) | 7 (11.9) | 25 (40.3) | 4 (7.1) | 14 (25.9) | 1 (3.7) | 4 (15.4) |
| Moderate periodontitis (%) | 22 (57.9) | 15 (39.5) | 35 (59.3) | 26 (41.9) | 22 (39.3) | 20 (37.0) | 9 (33.3) | 11 (42.3) |
| Severe periodontitis (%) | 2 (5.3) | 4 (10.5) | 17 (28.8) | 11 (17.7) | 30 (53.6) | 20 (37.0) | 17 (63.0) | 11 (42.3) |
| Moderate/severe periodontitis (%) | 24 (63.2) | 19 (50.0) | 52 (88.2) | 37 (59.6) | 52 (92.9) | 40 (74.0) | 26 (99.3) | 22 (84.6) |
| p-value | NS | | 0.002 | | 0.022 | | NS | |
| Periodontal parameters | | | | | | | | |
| Number of teeth (median, IQR) | 28 (1) | 28 (4) | 27 (3) | 27 (3) | 24 (5) | 24 (5) | 24 (5) | 22 (13) |
| p-value | NS | | NS | | NS | | NS | |
| FMPS (median, IQR) | 53.9 (32.5) | 46.4 (35.9) | 52.5 (40.5) | 44.5 (36.0) | 72.6 (39.2) | 53.7 (50.5) | 66.7 (49.9) | 60.4 (61.7) |
| p-value | NS | | NS | | NS | | NS | |
| FMBS (median, IQR) | 32.4 (42.5) | 24.5 (24.8) | 29.4 (39.1) | 28.7 (26.8) | 36.1 (37.9) | 30.4 (27.9) | 40.4 (61.0) | 26.6 (22.9) |
| p-value | NS | | NS | | NS | | NS | |
| Mean PPD (median, IQR) | 3.0 (0.9) | 2.5 (0.6) | 3.0 (0.7) | 2.6 (0.5) | 3.0 (0.5) | 2.7 (0.6) | 3.0 (1.1) | 2.9 (0.6) |
| p-value | NS | | 0.011 | | NS | | NS | |
| Mean CAL (median, | 3.0 (1.0) | 2.6 (0.5) | 3.1 (0.8) | 2.6 (0.6) | 3.1 (0.6) | 2.8 (0.9) | 3.3 (1.2) | 3.1 (1.1) |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| IQR) | | | | | | | | |
| p-value | NS | | 0.002 | | 0.021 | | NS | |
| Number of PPD ≥ 5 mm (median, IQR) | 2.5 (6.5) | 1.5 (6.2) | 9.0 (20.0) | 3.0 (11.2) | 10.5 (20.8) | 7.0 (26.2) | 9.0 (11.0) | 12.5 (19.2) |
| p-value | NS | | 0.027 | | NS | | NS | |

**Abbreviations:** IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; NS, non-statistically significant ($p > 0.05$); FMPS, full-mouth plaque score; FMBS, full-mouth bleeding score; PPD, probing pocket depth; CAL, clinical attachment level; IQR, interquartile range.

[a], IBD vs controls $p<0.001$; [b], CD vs UC $p<0.05$

**Table 4.** Final explorative logistic regression models for moderate/severe periodontitis

| Models and variables | OR | 95% (CI) | p-value |
|---|---|---|---|
| Model 1 | Periodontitis all sample (dichotomous) | | |
| Age | 1.05 | 1.02-1.06 | <0.001 |
| IBD | | | |
| No | 1 | | |
| Yes | 3.52 | 2.00-6.21 | <0.001 |
| FMPS | 1.02 | 1.01-1.03 | 0.003 |
| Model 2 [b] | Periodontitis only IBD (dichotomous) | | |
| Gender | | | |
| Female | 1 | | |
| Male | 3.42 | 1.27-9.24 | 0.015 |
| Age | 1.07 | 1.03-1.12 | <0.001 |
| IBD-associated surgery | | | |
| No | 1 | | |
| Yes | 0.028 | 0.10-0.79 | 0.016 |
| IBD localization | | | |
| Colon | 1 | | |
| Ileum | 1.79 | 0.52-6.15 | 0.354 |
| Ileum + colon | 3.39 | 1.00-11.53 | 0.05 |
| Model 3 [b] | Periodontitis only CD (dichotomous) | | |
| Gender | | | |
| Female | 1 | | |
| Male | 3.70 | 1.02-13.48 | 0.047 |
| Age | 1.07 | 1.02-1.12 | 0.009 |
| FMBS | 1.03 | 1.00-1.06 | 0.030 |
| CD localization | | | |
| Colon (L2) | 1 | | |
| Ileum (L1) | 2.98 | 0.68-13.14 | 0.149 |
| Ileum + colon (L3) | 7.07 | 1.50-33.46 | 0.014 |
| Model 4 [a] | Periodontitis only UC (dichotomous) | | |
| Age | 1.29 | 1.07-1.56 | 0.008 |
| UC duration | 0.79 | 0.65-0.98 | 0.028 |

| | | | |
|---|---|---|---|
| CD localization | | | |
| Localized (E1-E2) | 1 | | |
| Pancolitis (E3) | 21.65 | 1.11-420.16 | 0.042 |

**Abbreviations:** IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; FMPS, full-mouth plaque score; FMBS, full-mouth bleeding score; E1, proctitis; E2, left-sided UC; E3, pancolitis; L1, ileal; L2, colonic; L3, ileocolonic.

[a] , adjusted for gender and smoking status.

**Table 5.** Final explorative logistic regression models for IBD, CD and UC

| Models and variables | OR | 95% (CI) | p-value |
|---|---|---|---|
| Model 1 | IBD (dichotomous) | | |
| Smoking status | | | |
| Non-smoker | 1 | | |
| Light smoker | 0.49 | 0.26-0.94 | 0.031 |
| Heavy smoker | 0.69 | 0.38-1.24 | 0.212 |
| Periodontal diagnosis | | | |
| No/mild periodontitis | 1 | | |
| Moderate periodontitis | 3.21 | 1.80-5.72 | <0.001 |
| Severe periodontitis | 4.48 | 2.30-8.73 | <0.001 |
| FMBS (%) | 1.01 | 1.00-1.02 | 0.023 |
| Model 2 | CD (dichotomous) | | |
| Smoking status | | | |
| Non-smoker | 1 | | |
| Light smoker | 0.71 | 0.35-1.41 | 0.322 |
| Heavy smoker | 0.96 | 0.51-1.82 | 0.900 |
| Periodontal diagnosis | | | |
| No/mild periodontitis | 1 | | |
| Moderate periodontitis | 3.13 | 1.62-6.05 | 0.001 |
| Severe periodontitis | 4.01 | 1.92-8.38 | <0.001 |
| FMBS (%) | 1.01 | 1.00-1.02 | 0.048 |

| Model 3 | UC (dichotomous) | | |
|---|---|---|---|
| Smoking status | | | |
| Non-smoker | 1 | | |
| Light smoker | 0.14 | 0.03-0.63 | 0.010 |
| Heavy smoker | 0.34 | 0.13-0.90 | 0.030 |
| Periodontal diagnosis | | | |
| No/mild periodontitis | 1 | | |
| Moderate periodontitis | 3.14 | 1.32-7.47 | 0.010 |
| Severe periodontitis | 4.43 | 1.66-11.81 | 0.003 |
| FMBS (%) | 1.01 | 0.99-1.03 | 0.090 |

**Abbreviations:** IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; FMBS, full-mouth bleeding score.

Models adjusted for age, sex and education level.